CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease

August 9, 2026

DeepDNA USA

Overview

As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating significant clinical potential, with Intellia Therapeutics’ lonvoguran ziclumeran showing an 87% attack reduction in hereditary angioedema Phase 3 trials, and Verve Therapeutics’ VERVE-102 reducing cholesterol levels by up to 62%. The primary challenge remains precise delivery of editing tools to target cells and tissues, which currently confines approved therapies to blood and liver-targeting applications, underscoring delivery as the critical hurdle for future expansion.

In Depth

Key Findings

As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, promising clinical results are emerging from in vivo (in-body) therapies, with Intellia Therapeutics’ lonvoguran ziclumeran demonstrating an 87% reduction in attack frequency in a Phase 3 trial for hereditary angioedema, and Verve Therapeutics’ VERVE-102 reducing cholesterol levels by up to 62%.

Technical / Clinical Details

Approved ex vivo CRISPR therapies involve extracting hematopoietic stem cells from patients, genetically editing them outside the body, and then reinfusing them to correct the root cause of specific blood disorders. This approach shows high success rates because the gene-editing tools can reliably function within the controlled cellular environment. In contrast, in vivo CRISPR therapies aim to deliver gene-editing tools directly into the patient’s body to perform edits in target cells. Intellia Therapeutics’ lonvoguran ziclumeran, by editing the angiopoietin-like 3 gene in the liver, has shown remarkable data with an 87% reduction in hereditary angioedema attacks compared to placebo in its Phase 3 trial. Verve Therapeutics’ VERVE-102, by editing the PCSK9 gene, holds potential for treating hereditary hypercholesterolemia with up to a 62% reduction in LDL cholesterol. However, the primary challenge for in vivo therapies is the efficient and safe delivery of the CRISPR payload (gene-editing machinery) to the intended cells in the correct tissues. Currently, adeno-associated virus (AAV) vectors and lipid nanoparticles (LNPs) are the main delivery methods, but their tropism (affinity for specific organs) primarily to the liver and blood cells means that approved in vivo CRISPR therapies are currently limited to targeting these organs.

Background & Context

CRISPR gene-editing technology has brought about revolutionary changes in life science research and medical applications due to its high precision and efficiency. Since its first global approval in 2023, expectations for its clinical application have continued to grow. However, significant technical challenges remain for in vivo applications. Risks of off-target edits, immune reactions, and most critically, delivery challenges, impede its widespread applicability. Blood disorders and liver diseases have been the initial focus of in vivo therapy development due to relatively easier access to target cells. The evolution of delivery technologies will be a decisive factor for CRISPR therapies to expand to more complex diseases like neurological disorders, heart disease, and cancer.

Strategic Significance & Outlook

Future success in in vivo CRISPR therapy will contribute significantly to its application in diverse disease areas and improve treatment accessibility. The development of novel delivery vectors and advancements in tissue-specific targeting technologies will be key. For instance, research into non-viral vectors, new LNP technologies, or delivery systems leveraging cell-specific receptors is actively progressing. If these technical hurdles are overcome, CRISPR gene editing could evolve into a truly transformative medical modality, offering the potential for lifelong effects with a single treatment for many currently untreatable diseases. Regulatory bodies will also need to adapt their assessment frameworks for these novel therapies, considering both safety and efficacy.

Source: https://deepdna.ai/blog/crispr-complete-guide/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.